Steven C. Gilman, Director at Akebia Therapeutics, Inc. (AKBA), bought 5,800 shares at $3.43 ($20K) on 2019-11-20, disclosed to the SEC on 2019-11-22.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| VCEL | SELL | 2024-09-20 | $531K | — | Filing → |
| VCEL | SELL | 2024-09-05 | $243K | — | Filing → |
| AKBA | SELL | 2022-06-07 | $2K | — | Filing → |